medigraphic.com
ISSN 2007-8013 (Impreso)
Órgano oficial de la Universidad Autónoma de Sinaloa

2022, Número 4

<< Anterior Siguiente >>

Rev Med UAS 2022; 12 (4)


Estructura, señalización y regulación de la adiponectina en relación con la sensibilidad a la insulina y diabetes gestacional: Hallazgos clínicos y genéticos

López-Quintero AE, Cotero-de la Torre II, Bravo-Villagra KM, Herrera-Salazar A, Picos-Cárdenas VJ, Morgan-Ortíz F, Trapero-Corona IM, Muñoz-Valle JF, López-Quintero A

Idioma: Español
Referencias bibliográficas: 68
Paginas: 345-367
Archivo PDF: 686.19 Kb.


RESUMEN

El tejido adiposo sintetiza y secreta una serie de moléculas que intervienen en diversos procesos como la homeostasis energética, inmunidad e inflamación. La adiponectina está involucrada en el control de la homeostasis en tejidos sensibles a la insulina; se encuentra principalmente en circulación cómo oligómeros de distintos pesos moleculares que activan diversas vías de señalización. La implicación de adiponectina y sus isoformas en la regulación de la homeostasis energética y su posible uso como biomarcador pronóstico en la sensibilidad a la insulina generan la necesidad de conocer el impacto de intervenciones que modifiquen sus niveles circulantes o de expresión. Este conocimiento es particularmente importante en la búsqueda de estrategias para mejorar el estado metabólico de sujetos en condiciones metabólicas alteradas como la diabetes gestacional. Por lo que el objetivo de esta revisión fue integrar el conocimiento para mejorar la comprensión sobre la regulación de adiponectina y su aplicación clínica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin re-sistance. Clin Chim Acta. 2013 Feb;417:80–4.

  2. Tsiotra PC, Halvatsiotis P, Patsouras K, Maratou E, Salamalekis G, Raptis SA, et al. Circulating adipokines and mRNA expres-sion in adipose tissue and the placenta in women with gestational diabetes mellitus. Peptides. 2018 Mar;101:157–66.

  3. Xita N, Tsatsoulis A. Adiponectin in Diabetes Mellitus. Curr Med Chem. 2012 Oct 1;19(32):5451–8.

  4. Katsiki N, Mantzoros C, Mikhailidis DP. Adi-ponectin, lipids and atherosclerosis. Curr Opin Lipidol. 2017 Aug;28(4):347–54.

  5. Diep Nguyen T. Adiponectin: Role in physi-ology and pathophysiology. Int J Prev Med. 2020;11(1):136.

  6. Gu W, Li Y. The Therapeutic Potential of the Adiponectin Pathway. 2012;8.

  7. Combs TP, Marliss EB. Adiponectin signal-ing in the liver. Rev Endocr Metab Disord. 2014 Jun;15(2):137–47.

  8. Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol. 2016 Apr;8(2):101–9.

  9. Liu M, Liu F. Regulation of adiponectin mul-timerization, signaling and function. Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):25–31.

  10. Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13(1):103.

  11. Caselli C. Role of adiponectin system in in-sulin resistance. Mol Genet Metab. 2014 Nov;113(3):155–60.

  12. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: Regulation of its production and its role in human diseases. Hormones. 2012 Jan;11(1):8–20.

  13. Cheng KKY, Lam KSL, Wang B, Xu A. Sig-naling mechanisms underlying the insulin-sensitizing effects of adiponectin. Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):3–13.

  14. Fu Y. Adiponectin Signaling and Metabolic Syndrome. In: Progress in Molecular Biology and Translational Science [Internet]. Else-vier; 2014 [cited 2022 Jan 24]. p. 293–319. Available from: https://n9.cl/0tofm

  15. Esmaili S, Hemmati M, Karamian M. Physio-logical role of adiponectin in different tissues: a review. Arch Physiol Biochem. 2020 Jan 1;126(1):67–73.

  16. Yamauchi T, Iwabu M, Okada-Iwabu M, Ka-dowaki T. Adiponectin receptors: A review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):15–23.

  17. Roy B, Palaniyandi SS. Tissue-specific role and associated downstream signaling path-ways of adiponectin. Cell Biosci. 2021 Dec;11(1):77.

  18. J. Hickman I, P. Whitehead J. Structure, Sig-nalling and Physiologic Role of Adiponectin-Dietary and Exercise- Related Variations. Curr Med Chem. 2012 Oct 1;19(32):5427–43.

  19. Aye ILMH, Powell TL, Jansson T. Review: Adiponectin – The missing link between ma-ternal adiposity, placental transport and fetal growth? Placenta. 2013 Mar;34:S40–5.

  20. Choi HM, Doss HM, Kim KS. Multifaceted Physiological Roles of Adiponectin in Inflam-mation and Diseases. Int J Mol Sci. 2020 Feb 12;21(4):1219.

  21. Van Andel M, Heijboer AC, Drent ML. Adi-ponectin and Its Isoforms in Pathophysiol-ogy. In: Advances in Clinical Chemistry [In-ternet]. Elsevier; 2018 [cited 2022 Jan 24]. p. 115–47. Available from: https://n9.cl/6caap

  22. Tabb KL, Gao C, Hicks PJ, Hawkins GA, Rotter JI, Chen Y-DI, et al. Adiponectin Iso-form Patterns in Ethnic-Specific ADIPOQ Mutation Carriers: The IRAS Family Study:Adiponectin Isoforms in ADIPOQ Mutation Carriers. Obesity. 2017 Aug;25(8):1384–90.

  23. Fang H, Judd RL. Adiponectin Regulation and Function. In: Terjung R, editor. Compre-hensive Physiology [Internet]. 1st ed. Wiley; 2018 [cited 2022 Jan 24]. p. 1031–63. Avail-able from: https://n9.cl/a4ckf

  24. Balsan GA, Vieira JL da C, Oliveira AM de, Portal VL. Relationship between adiponec-tin, obesity and insulin resistance. Rev As-soc Médica Bras. 2015 Feb;61(1):72–80.

  25. Tishinsky JM, Robinson LE, Dyck DJ. Insu-lin-sensitizing properties of adiponectin. Bio-chimie. 2012 Oct;94(10):2131–6.

  26. Jaganathan R, Ravindran R, Dhanasekaran S. Emerging Role of Adipocytokines in Type 2 Diabetes as Mediators of Insulin Re-sistance and Cardiovascular Disease. Can J Diabetes. 2018 Aug;42(4):446-456.

  27. Engin A. Adiponectin-Resistance in Obesity. In: Engin AB, Engin A, editors. Obesity and Lipotoxicity [Internet]. Cham: Springer Inter-national Publishing; 2017 [cited 2022 Jan 24]. p. 415–41. (Advances in Experimental Medicine and Biology; vol. 960). Available from: https://n9.cl/4flst

  28. Zhao L, Fu Z, Liu Z. Adiponectin and insulin cross talk: The microvascular connection. Trends Cardiovasc Med. 2014 Nov;24(8):319–24.

  29. Park SE, Park C-Y, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: Past, present and future. Crit Rev Clin Lab Sci. 2015 Jul 4;52(4):180–90.

  30. Stears A, O’Rahilly S, Semple RK, Savage DB. Metabolic insights from extreme human insulin resistance phenotypes. Best Pract Res Clin Endocrinol Metab. 2012 Apr;26(2):145–57.

  31. Mather KJ, Goldberg RB. Clinical use of ad-iponectin as a marker of metabolic dysregu-lation. Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):107–17.

  32. De Gennaro G, Palla G, Battini L, Simoncini T, Del Prato S, Bertolotto A, et al. The role of adipokines in the pathogenesis of gesta-tional diabetes mellitus. Gynecol Endocrinol. 2019 Sep 2;35(9):737–51.

  33. De Luis DA, Izaola O, Primo D, Aller R. Sin-gle nucleotide polymorphisms at the ADI-POQ gene locus rs1501299 interact with dif-ferent type of dietary fatty acids in two hy-pocaloric diets. 2019; 23: 2960-2970

  34. AlSaleh A, Sanders TAB, O’Dell SD. Effect of interaction between PPARG, PPARA and ADIPOQ gene variants and dietary fatty ac-ids on plasma lipid profile and adiponectin concentration in a large intervention study. Proc Nutr Soc. 2012 Feb;71(1):141–53.

  35. Aller R, Izaola O, Primo D, de Luis DA. The effect of single-nucleotide polymorphisms at the ADIPOQ gene locus rs1501299 on met-abolic parameters after 9 mo of a high-pro-tein/low-carbohydrate versus a standard hy-pocaloric diet. Nutrition. 2019 Sep;65:44–9.

  36. Lowry DE, Fenwick PH, Roke K, Jeejeebhoy K, Dhaliwal R, Brauer P, et al. Variants in APOA5 and ADIPOQ Moderate Improve-ments in Metabolic Syndrome during a One-Year Lifestyle Intervention. Lifestyle Geno-mics. 2018;11(2):80–9.

  37. De Luis DA, Izaola O, Primo D, Gómez-Ho-yos E, Ortola A, López-Gómez JJ, et al. Role of rs1501299 variant in the adiponectin gene on total adiponectin levels, insulin resistance and weight loss after a Mediterranean hy-pocaloric diet. Diabetes Res Clin Pract. 2019 Feb;148:262–7.

  38. De Luis DA, Primo D, Izaola O. Adiponectin gene variant rs266729 interacts with differ-ent macronutrient distributions of two differ-ent hypocaloric diets during nine months. Nutr Hosp [Internet]. 2021 [cited 2022 Jan 24]; Available from: https://n9.cl/zb0nk

  39. Siitonen N, Pulkkinen L, Lindström J, Kolehmainen M, Eriksson JG, Venojärvi M, et al. Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Dia-betes Prevention Study. BMC Med Genet. 2011 Dec;12(1):5.

  40. De Luis DA, Primo D, Izaola O, Aller R. Adi-ponectin Gene Variant rs266729 Interacts with Different Macronutrient Distribution of Two Different Hypocaloric Diets. Lifestyle Genomics. 2019 Nov;11(1):8–1.

  41. Sun Y, Li D, Li Q, Huang L, He Z, Zhang F, et al. Relationship between ADIPOQ gene polymorphism and lipid levels and diabetes. Biological Regulators. 2015 Feb;29(1):183–177.

  42. Du W, Li Q, Lu Y, Yu X, Ye X, Gao Y, et al. Genetic variants in ADIPOQ gene and the risk of type 2 diabetes: a case–control study of Chinese Han population. Endocrine. 2011 Dec;40(3):413–22.

  43. Kitamoto A, Kitamoto T, So R, Matsuo T, Na-kata Y, Hyogo H, et al. ADIPOQ polymor-phisms are associated with insulin re-sistance in Japanese women. Endocr J. 2015;62(6):513–21.

  44. Nomani H, Hesami O, Vaisi‐Raygani A, Tanhapour M, Bahrehmand F, Rahimi Z, et al. Association between the −11377 C/G and −11391 G/A polymorphisms of adiponectin gene and adiponectin levels with susceptibil-ity to type 1 and type 2 diabetes mellitus in population from the west of Iran, correlation with lipid profile. J Cell Biochem. 2019 Mar;120(3):3574–82.

  45. Belalcazar LM, Papandonatos GD, McCaffery JM, Peter I, Pajewski NM, Erar B, et al. A common variant in the CLDN7/ELP5 locus predicts adiponectin change with life-style intervention and improved fitness in obese individuals with diabetes. Physiol Ge-nomics. 2015 Jun;47(6):215–24.

  46. Lee K-Y, Kang H-S, Shin Y-A. Exercise im-proves adiponectin concentrations irrespec-tive of the adiponectin gene polymorphisms SNP45 and the SNP276 in obese Korean women. Gene. 2013 Mar;516(2):271–6.

  47. Hellwege JN, Palmer ND, Brown MW, Zieg-ler JT, An SS, Guo X, et al. Empirical char-acteristics of family-based linkage to a com-plex trait: the ADIPOQ region and adiponec-tin levels. Hum Genet. 2015 Feb;134(2):203–13.

  48. Baril-Gravel L, Labonté M-E, Couture P, Vohl M-C, Charest A, Guay V, et al. Do-cosahexaenoic acid-enriched canola oil in-creases adiponectin concentrations: A ran-domized crossover controlled interventiontrial. Nutr Metab Cardiovasc Dis. 2015 Jan;25(1):52–9.

  49. Perfilyev A, Dahlman I, Gillberg L, Rosqvist F, Iggman D, Volkov P, et al. Impact of poly-unsaturated and saturated fat overfeeding on the DNA-methylation pattern in human adipose tissue: a randomized controlled trial. Am J Clin Nutr. 2017 Apr;105(4):991–1000.

  50. Moran CN, Barwell ND, Malkova D, Cleland SJ, McPhee I, Packard CJ, et al. Effects of diabetes family history and exercise training on the expression of adiponectin and leptin and their receptors. Metabolism. 2011 Feb;60(2):206–14.

  51. Moghadasi M, Mohebbi H, Rahmani-Nia F, Hassan-Nia S, Noroozi H, Pirooznia N. High-intensity endurance training improves adi-ponectin mRNA and plasma concentrations. Eur J Appl Physiol. 2012 Apr;112(4):1207–14.

  52. Aslfalah H, Jamilian M, Khosrowbeygi A. El-evation of the adiponectin/leptin ratio in women with gestational diabetes mellitus af-ter supplementation with alpha-lipoic acid. Gynecol Endocrinol. 2019 Mar 4;35(3):271–5.

  53. Corrado F, D’Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, et al. The effect of myoinositol supplementation on insulin re-sistance in patients with gestational diabe-tes: Supplementation of myoinositol in ges-tational diabetes. Diabet Med. 2011 Aug;28(8):972–5.

  54. Luoto R, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counseling during pregnancy on co-lostrum adiponectin concentration: A pro-spective, randomized, placebo-controlled study. Early Hum Dev. 2012 Jun;88(6):339–44.

  55. Aviram A, Shtaif B, Gat-Yablonski G, Yogev Y. The association between adipocytokines and glycemic control in women with gesta-tional diabetes mellitus. J Matern Fetal Neo-natal Med. 2020 Jan 17;33(2):177–83.

  56. White SL, Lawlor DA, Briley AL, Godfrey KM, Nelson SM, Oteng-Ntim E, et al. Early Ante-natal Prediction of Gestational Diabetes in Obese Women: Development of Prediction Tools for Targeted Intervention. PLoS ONE.M2016 Dec 8;11(12):e0167846.

  57. Migda M, Migda MS, Migda B, Krzyżan-owska P, Wender-Ożegowska E. Compo-nents of metabolic syndrome in the first tri-mester of pregnancy as predictors of ad-verse perinatal outcome. Ginekologia Polska 2016;87(9): 644–650.

  58. Mousa A, Abell SK, Shorakae S, Harrison CL, Naderpoor N, Hiam D, et al. Relationship between vitamin D and gestational diabetes in overweight or obese pregnant women may be mediated by adiponectin. Mol Nutr Food Res. 2017 Nov;61(11):1700488.

  59. Li L-J, Rifas-Shiman SL, Aris IM, Young JG, Mantzoros C, Hivert M-F, et al. Associations of maternal and cord blood adipokines with offspring adiposity in Project Viva: is there an interaction with child age? Int J Obes. 2018 Apr;42(4):608–17.

  60. Migda M, Migda MS, Migda B, Wender-Oze-gowska E. Maternal First trimester parame-ters in the prediction of excessive fetal growth in pregnant women with metabolicsyndrome. Physiology Pharma. 2017;68(6):839-833.

  61. Noreña I, Pardo MP, Mockus I. Niveles séri-cos de adipocitocinas y resistencia a la insu-lina en el primer trimestre de gestación en adolescentes y su relación con el peso del recién nacido. Biomédica. 2018 Sep 1;38(3):427–36.

  62. Maitland RA, Seed PT, Briley AL, Homsy M, Thomas S, Pasupathy D, et al. Prediction of gestational diabetes in obese pregnant women from the UK Pregnancies Better Eat-ing and Activity (UPBEAT) pilot trial. Diabet Med. 2014 Aug;31(8):963–70.

  63. Kim C, Christophi CA, Goldberg RB, Per-reault L, Dabelea D, Marcovina SM, et al. Adiponectin, C-reactive protein, fibrinogen and tissue plasminogen activator antigen levels among glucose-intolerant women with and without histories of gestational diabetes. Diabet Med. 2016 Jan;33(1):32–8.

  64. Durnwald CP, Downes K, Leite R, Elovitz M, Parry S. Predicting persistent impaired glu-cose tolerance in patients with gestational di-abetes: The role of high sensitivity CRP and adiponectin. Diabetes Metab Res Rev. 2018 Feb;34(2):e2958.

  65. Honnorat D, Disse E, Millot L, Mathiotte E, Claret M, Charrie A, et al. Are third-trimester adipokines associated with higher metabolic risk among women with gestational diabe-tes? Diabetes Metab. 2015 Nov;41(5):393–400.

  66. Mehmood S, Ye C, Connelly PW, Hanley AJ, Zinman B, Retnakaran R. Rising plasmino-gen activator inhibitor-1 and hypoadiponecti-nemia characterize the cardiometabolic bi-omarker profile of women with recent gesta-tional diabetes. Cardiovasc Diabetol. 2018 Dec;17(1):133.

  67. Gunderson EP, Kim C, Quesenberry CP, Marcovina S, Walton D, Azevedo RA, et al. Lactation intensity and fasting plasma lipids, lipoproteins, non-esterified free fatty acids, leptin and adiponectin in postpartum women with recent gestational diabetes mellitus: The SWIFT cohort. Metabolism. 2014 Jul;63(7):941–50.

  68. Sun X, Sun H, Zhang J, Ji X. Artemisia Ex-tract Improves Insulin Sensitivity in Women With Gestational Diabetes Mellitus by Up-Regulating Adiponectin: Artemisia Improves Insulin Sensitivity in GDM. J Clin Pharmacol. 2016 Dec;56(12):1550–4.




2020     |     www.medigraphic.com